Advanced and Metastatic Solid Tumors, IMM-1-104

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors.

Colorectal, A221805

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Patient Newsletter 2024 April

CBD Frequently Asked Questions

Patient Newsletter 2024 March

Free Colorectal Cancer Forum

SOLD OUT- HOA and Associated Gastroenterologists of CNY Offer Patient Education Forum

about Colorectal Cancer Prevention and Treatment on Tuesday, April 16 - SOLD OUT

HOA Constructing New Comprehensive Cancer Center in Camillus

HOA Constructing New Comprehensive Cancer Center in Camillus

Camillus, NY – Hematology-In May 2023 Hematology-Oncology Associates of CNY (HOA) celebrated the beginning of building their future 21,000 square foot comprehensive cancer center in Camillus, NY. The new building will be located at 5490 Cobbler Way, and will replace the current Onondaga Hill location.  HOA is planning to open the center in September 2024.

Dr. Kumar Discusses Gallbaldder Cancer

Dr. Kumar Discusses

Gallbladder Cancer

Dr. Kumar Discusses Gallbladder Cancer

Pages